Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: A prospective randomized controlled trial

International Journal of Infectious Diseases

Volumn 48, Issue , 2016, Pages 40-45

  Wang, Jin Xiang ^a   Zhang, Shu Ming ^a   Li, Xiao Hui ^a   Zhang, Yao ^b   Xu, Zhen Yang ^a   Cao, Bin ^a,c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d Center of Respiratory Medicine   (China)

Author keywords

Acute exacerbation; Antibiotics; Chronic obstructive pulmonary disease; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; LEVOFLOXACIN; PIPERACILLIN; PROCALCITONIN; SULBACTAM; ANTIINFECTIVE AGENT; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR;

ADULT; AGED; ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROL GROUP; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ACUTE DISEASE; BLOOD; HOSPITALIZATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84969851012     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.04.024     Document Type: Short Survey

References (23)

1. Zhong N., Wang C., Yao W., Chen P., Kang J., Huang S., et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007, 176:753-760.
2. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2014. Available at: (accessed on May 14, 2014). http://www.goldcopd.org/.
3. He Q.Y., Zhou X., Xie C.M., Liang Z.A., Chen P., Wu C.G. [Impact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areas]. Zhong Hua Jie He He Hu Xi Za Zhi 2009, 32:253-257.
4. Lou P., Zhu Y., Chen P., Zhang P., Yu J., Zhang N., et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health 2012, 12:287.
5. Lindenauer P.K., Pekow P., Gao S., Crawford A.S., Gutierrez B., Benjamin E.M. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006, 144:894-903.
6. Lopez-Campos J.L., Hartl S., Pozo-Rodriguez F., Roberts C.M. Antibiotic prescription for COPD exacerbations admitted to hospital: European COPD audit. PLoS One 2015, 10:e0124374.
7. Quon B.S., Gan W.Q., Sin D.D. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008, 133:756-766.
8. Rothberg M.B., Pekow P.S., Lahti M., Brody O., Skiest D.J., Lindenauer P.K. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010, 303:2035-2042.
9. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
10. Vollenweider D.J., Jarrett H., Steurer-Stey C.A., Garcia-Aymerich J., Puhan M.A. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 12:CD010257.
11. Stockley R.A., O'Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000, 117:1638-1645.
12. Soler N., Esperatti M., Ewig S., Huerta A., Agusti C., Torres A. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012, 40:1344-1353.
13. Nouira S., Marghli S., Belghith M., Besbes L., Elatrous S., Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001, 358:2020-2025.
14. Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M.M., Huber P.R., Tamm M., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
15. Stolz D., Christ-Crain M., Bingisser R., Leuppi J., Miedinger D., Muller C., et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131:9-19.
16. Schuetz P., Christ-Crain M., Thomann R., Falconnier C., Wolbers M., Widmer I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
17. Daniels J.M., Schoorl M., Snijders D., Knol D.L., Lutter R., Jansen H.M., et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010, 138:1108-1115.
18. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987, 136:225-244. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.
19. Daniels J.M., Snijders D., de Graaff C.S., Vlaspolder F., Jansen H.M., Boersma W.G. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:150-157.
20. Chow A.W., Hall C.B., Klein J.O., Kammer R.B., Meyer R.D., Remington J.S. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15(Suppl 1):S62-S88.
21. Llor C., Moragas A., Hernandez S., Bayona C., Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:716-723.
22. Miravitlles M., Anzueto A., Ewig S., Legnani D., Stauch K. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study. Ther Adv Respir Dis 2009, 3:267-277.
23. Miravitlles M., Moragas A., Hernandez S., Bayona C., Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?. Chest 2013, 144:1571-1577.